Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.74 |
| ▸ | CA1 | P00915 | 3/20 | 0.74 |
| ▸ | CA2 | P00918 | 3/20 | 0.74 |
| ▸ | CA9 | Q16790 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.70 |
| ▸ | MEN1 | O00255 | 5/20 | 0.70 |
| ▸ | POLB | P06746 | 5/20 | 0.66 |
| ▸ | CASP6 | P55212 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | CLTC | Q00610 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.59 |
| ▸ | BRD1 | O95696 | 1/20 | 0.58 |
| ▸ | TAF1 | P21675 | 1/20 | 0.58 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.58 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.58 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | NGFR | P08138 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5144919 | 0.91 | SCN2A (0.70) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL14159191 | 0.88 | CA12 (0.73) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL4235535 | 0.88 | CLTC (0.73) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL4235316 | 0.87 | MEN1 (0.89) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL5161227 | 0.85 | MEN1 (0.75) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL5533314 | 0.85 | CA12 (0.79) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL5160430 | 0.85 | CA12 (0.69) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL5529962 | 0.85 | MAPT (0.68) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL14533642 | 0.85 | CA12 (0.69) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL5162915 | 0.85 | CA12 (0.65) | CA12CA1CA2CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140127137-A1 | SMMR (SMALL MOLECULE METABOLITE REPORTERS) FOR USE AS IN VIVO GLUCOSE BIOSENSORS | Cercacor Laboratories, Inc (US) | 2014-05-08 | — | — | US | disclosed |
| US-8466286-B2 | SMMR (small molecule metabolite reporters) for use as in vivo glucose biosensors | CERCACOR LABORATORIES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120052018-A1 | SMMR (SMALL MOLECULE METABOLITE REPORTERS) FOR USE AS IN VIVO GLUCOSE BIOSENSORS | MASIMO LABORATORIES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-8029765-B2 | SMMR (small molecule metabolite reporters) for use as in vivo glucose biosensors | MASIMO LABORATORIES, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8008088-B2 | SMMR (small molecule metabolite reporters) for use as in vivo glucose biosensors | MASIMO LABORATORIES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090215814-A1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-08-27 | — | — | US | disclosed |
| US-20090004108-A1 | Smmr (Small Molecule Metabolite Reporters) For Use As In Vivo Glucose Biosensors | MASIMO LABORATORIES, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20070110672-A1 | SMMR (small molecule metabolite reporters) for use as in vivo glucose biosensors | CERCACOR LABORATORIES, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070078137-A1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-04-05 | — | — | US | disclosed |
| US-7148352-B2 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-12-12 | — | — | US | disclosed |
| WO-2005065241-A2 | SMMR (SMALL MOLECULE METABOLITE REPORTERS) FOR USE AS IN VIVO GLUCOSE BIOSENSORS | ARGOSE, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20030186901-A1 | Method of inhibiting neurotrophin-receptor binding | MINE SAFETY APPLIANCES COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-6468990-B1 | ADMINISTERING COMPOUNDS HAVING ELECTRONEGATIVE GROUPS WHICH INTERACT WITH CERTAIN LYSINE RESIDUES IN NERVE GROWTH FACTOR AND/OR HYDROPHOBIC MOIETY WHICH INTERACTS WITH HYDROPHOBIC REGION FORMED BY CERTAIN ISOLEUCINE AND PHENYLALANINE RESIDUES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-10-22 | — | — | US | disclosed |
| EP-1226121-A1 | METHOD OF INHIBITING NEUROTROPHIN-RECEPTOR BINDING | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-07-31 | — | — | EP | disclosed |
| WO-2000069829-A1 | METHOD OF INHIBITING NEUROTROPHIN-RECEPTOR BINDING | QUEEN'S UNIVERSITY (CA) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215814-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | CA12 2567/4885CA1 1178/4885CA2 1798/4885 |
| US-20140127137-A1 | SMMR (SMALL MOLECULE METABOLITE REPORTERS) FOR USE AS IN VIVO GLUCOSE BIOSENSORS | GCKR, SYMPK, SUCNR1 | CA12 570/4885CA1 2608/4885CA2 723/4885 |
| US-20070110672-A1 | SMMR (small molecule metabolite reporters) for use as in vivo glucose biosensors | GCKR, SYMPK, SUCNR1 | CA12 570/4885CA1 2608/4885CA2 723/4885 |
| US-20070078137-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | CA12 2567/4885CA1 1178/4885CA2 1798/4885 |
| US-20120052018-A1 | SMMR (SMALL MOLECULE METABOLITE REPORTERS) FOR USE AS IN VIVO GLUCOSE BIOSENSORS | GCKR, SYMPK, SUCNR1 | CA12 570/4885CA1 2608/4885CA2 723/4885 |
| US-20030186901-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | CA12 2650/4885CA1 1142/4885CA2 1630/4885 |
| US-20090004108-A1 | Smmr (Small Molecule Metabolite Reporters) For Use As In Vivo Glucose Biosensors | GCKR, SYMPK, SUCNR1 | CA12 570/4885CA1 2608/4885CA2 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.